Introduction

Imagine your child’s body is engaged in a relentless, internal battle, one that can’t be seen, but whose effects are all too real. Crohn's disease is far more than occasional abdominal pain; it is a chronic inflammatory condition where the immune system mistakenly attacks the digestive tract.

While managing symptoms is crucial, what if you could address the problem at its source? Crohn's is a systemic disease, with consequences that extend beyond the gut, potentially affecting a child's nutrition, growth, and overall well-being. But what if there was a strategic way to help the immune system find a healthier, more balanced state?

This is the fundamental promise of immunomodulators. These specialised medications are designed to precisely modulate the overactive immune response, quieting the underlying inflammation that drives the disease process and allows the intestinal lining to heal.

What are immunomodulators?

Immunomodulators are a class of therapeutics that modify the underlying immune activity in Crohn's disease. Their primary mechanism involves correcting the dysregulated immune response responsible for attacking the gastrointestinal tract. They achieve this by tempering the overproduction and function of specific white blood cells and pro-inflammatory signalling molecules.

It is important to distinguish these agents from short-term therapies like corticosteroids. Immunomodulators are not intended for immediate symptom relief but are rather foundational for long-term disease management. Their objective is to induce and maintain sustained remission.¹ In paediatric patients, this sustained control is critically important, as it directly supports crucial developmental milestones, including linear growth, nutritional status, and pubertal development.

Therapeutic goals of immunomodulators in pediatric crohn's disease

The use of immunomodulators in children extends beyond short-term symptom relief to achieve fundamental, long-term health outcomes. The primary objectives of this treatment strategy are:

• To Achieve and Sustain Disease Remission: The central goal is to actively suppress intestinal inflammation to induce clinical remission and, critically, to maintain it over time. This prevents disease flare-ups and ensures prolonged periods of wellness
• To serve as a Steroid-Sparing Strategy, A key objective is to reduce or eliminate the need for corticosteroids. This mitigates the risk of significant side effects associated with steroids, particularly growth suppression, which is a major concern in the pediatric population²
• To Facilitate Normal Growth and Development: Effective disease control creates the metabolic stability necessary for catch-up growth and normal progression through puberty. By resolving chronic inflammation and improving nutrient absorption, these therapies directly support a child's physical maturation
• To Prevent Long-Term Complications: Persistent inflammation can lead to severe complications such as strictures, fistulas, and hospitalisations. Immunomodulators lower the risk of these outcomes by providing continuous control of the underlying disease process, thereby preserving intestinal health³
• To Restore Overall Quality of Life: Ultimately, the comprehensive aim is to enable full participation in childhood activities. With controlled disease, children can consistently attend school, engage in sports, and enjoy social interactions, leading to a significant improvement in their overall well-being

Classification of immunomodulators in pediatric crohn’s disease

Three main classes are used in paediatric care.⁴

• Thiopurines
  • Azathioprine (AZA)
  • 6-Mercaptopurine (6-MP)
• Methotrexate
• Calcineurin Inhibitors
  • Cyclosporine
  • Tacrolimus

Thiopurines: azathioprine and 6-mercaptopurine

Molecular pharmacology

Thiopurines exert their immunosuppressive effects through a multi-step metabolic activation process. Following oral administration, azathioprine undergoes rapid non-enzymatic conversion to mercaptopurine, which then enters the purine salvage pathway. The critical activation occurs via hypoxanthine-guanine phosphoribosyltransferase (HGPRT), converting mercaptopurine to thioinosine monophosphate (TIMP). This metabolite undergoes further phosphorylation and conversion to active thioguanine nucleotides (TGNs), which incorporate into DNA and RNA, causing chain termination and inhibition of purine synthesis. Additionally, methylated metabolites (MMPR) inhibit de novo purine synthesis, while TIMP accumulation suppresses Rac1 activation, inducing T-cell apoptosis through mitochondrial pathways.⁵

Clinical pharmacokinetics

• Absorption: Azathioprine demonstrates 50-90% oral bioavailability with peak concentrations achieved within 1-2 hours. Mercaptopurine shows variable absorption (5-37%) due to extensive first-pass metabolism.
• Distribution: Wide tissue distribution with a volume of distribution of approximately 0.8 L/kg. Minimal protein binding (20-30%) allows for efficient tissue penetration
• Metabolism: Hepatic metabolism occurs via three competing pathways that significantly influence metabolic capacity and toxicity risks
• Elimination: Renal excretion accounts for 80% of elimination

Therapeutic considerations

• Dosing: Initial dose 1.0-2.5 mg/kg/day for azathioprine, 1.0-1.5 mg/kg/day for mercaptopurine
• Drug Interactions: Allopurinol (potent xanthine oxidase inhibitor) requires a 75% dose reduction

Adverse effects management

• Haematological: Weekly CBC monitoring initially, then monthly
• Hepatotoxicity
• Pancreatitis: Immediate discontinuation if abdominal pain with amylase/lipase elevation⁶

Methotrexate

Mechanistic pharmacology

Methotrexate is a powerful medicine that helps “retrain” the immune system when it becomes too active, as often happens in Crohn’s disease. Instead of simply blocking inflammation, it works through several smart steps to calm the immune response from the inside out.

At low doses, methotrexate boosts the levels of a natural chemical called adenosine, a messenger that tells immune cells to slow down and stop producing harmful inflammatory signals like TNF-α, IL-6, and IL-8. These signals are usually responsible for swelling, pain, and damage in the gut.

It also blocks certain building blocks that immune cells need to grow and multiply. This means fewer aggressive immune cells are available to attack the body. On top of that, methotrexate can switch off overactive T-cells, key players in immune attacks and even encourage them to die when they’re no longer needed.

Together, these actions help reduce inflammation, protect the gut lining, and support long-term healing.

Pharmacokinetic profile

This section explains how methotrexate behaves inside the body, how it’s absorbed, distributed, broken down, and removed:

• Absorption: When taken by mouth, the body absorbs it only partly, and the amount can vary. If given as an injection under the skin, absorption is much more reliable (about 85–90%).
• Distribution: Once in the bloodstream, methotrexate travels widely through body tissues and can build up slowly with repeated doses
• Metabolism: The liver breaks down only a small amount of it into a substance called 7-hydroxymethotrexate
• Elimination: Most of the drug is removed from the body by the kidneys through urine

Clinical application

Doctors use methotrexate as a long-term treatment to control inflammation and help maintain remission. Here’s how it’s typically used:

• Dosing: Usually given once a week as a small injection under the skin
• Supplementation: Patients also take folic acid daily (except on methotrexate day) to reduce side effects
• Monitoring: Regular blood tests are essential, usually once a month, to check blood cell counts, liver and kidney function. If the total amount taken over time gets very high, doctors may recommend a liver biopsy to check for any hidden damage

Toxicity profile

Like all powerful medicines, methotrexate can have side effects, but with careful monitoring, most are manageable:

• Gastrointestinal: Some people feel sick or develop mouth sores. Taking folic acid helps reduce these problems
• Liver: Long-term use can sometimes lead to scarring (fibrosis) of the liver, especially with high cumulative doses
• Lungs: Rarely, methotrexate can cause inflammation in the lungs. If this happens, the medicine must be stopped immediately
• Pregnancy: Methotrexate can cause birth defects, so strict contraception is essential while on treatment⁷

Calcineurin inhibitors: cyclosporine and acrolimus

Molecular mechanisms

Cyclosporine and tacrolimus are two powerful medicines used to calm an overactive immune system, especially when standard treatments aren’t enough. Think of them as “off switches” for the body’s immune alarm.

They work by blocking a key signal inside immune cells called calcineurin, which normally tells T-cells to start producing inflammation-causing chemicals. Cyclosporine and tacrolimus do this in slightly different ways: cyclosporine teams up with a helper protein called cyclophilin, while tacrolimus pairs with FKBP-12. Once they’ve formed this partnership, they stop calcineurin from working.

Without calcineurin’s signal, the immune system slows down its production of inflammatory messages like IL-2 and IL-4, which means fewer activated T-cells attacking the body. These medicines also protect cells from stress and damage by reducing harmful molecules inside them. Overall, the result is less inflammation and more control over immune activity, which is exactly what’s needed in conditions like Crohn’s disease.⁸

Pharmacokinetic characteristics

This part explains how the body handles these medicines:

• Absorption: How much is absorbed can vary from person to person, especially if food or other factors are involved
• Distribution: Once in the bloodstream, they spread widely throughout the body and attach to blood cells and tissues
• Metabolism: The liver breaks them down using special enzymes before they’re removed from the body
• Elimination: Most of the drug leaves the body through bile and stool rather than urine⁹

Therapeutic monitoring

Because these drugs are powerful, doctors closely monitor their levels in the blood to make sure they’re working effectively but safely.

• Cyclosporine: The Target blood level is usually 100–200 ng/mL
• Tacrolimus: The Target blood level is usually 5–15 ng/mL

Blood tests are done frequently at the start of treatment, often daily, and then less often once the dose is stable.

Adverse effects and management

Like all strong medicines, cyclosporine and tacrolimus can cause side effects. Most are manageable when caught early:

• Kidney effects: They can affect how the kidneys work, so regular kidney function tests are important
• Nervous system: Tremors or headaches can happen in some people. Rarely, more serious brain effects may occur
• Metabolic changes: Blood pressure, cholesterol, or blood sugar levels might rise, so these are monitored too
• Infections: Because they lower the immune response, the risk of infections increases so preventive care is important¹⁰

Drug interactions

These medicines can interact with many other drugs, so it’s crucial to tell your healthcare provider about everything you’re taking.

• Certain antibiotics or antifungals can increase drug levels
• Some seizure medicines or rifampin can lower their effectiveness
• Other kidney-affecting drugs (like NSAIDs or certain antibiotics) can increase the risk of kidney damage

Combining immunomodulators with biologics

In today’s treatment of paediatric inflammatory bowel disease (IBD), especially moderate to severe cases, doctors often use two types of medicines together: immunomodulators and biologics.

Biologics like infliximab and adalimumab are advanced treatments that target specific parts of the immune system to reduce inflammation. Immunomodulators work by calming down an overactive immune response. When used as a team, they make each other more effective.¹¹

One of the key benefits of this combination is that immunomodulators can prevent the body from creating antibodies against biologic medicines. This means the biologic can work properly for a longer time. For children with more aggressive disease, this often leads to better long-term results, including more consistent remission (when symptoms disappear) and better healing of the gut lining.

Risk-benefit analysis

When planning treatment, doctors carefully weigh the benefits of using immunomodulators against their possible risks. These medicines can sometimes cause side effects, but the consequences of untreated Inflammatory bowel diseases are usually much more serious.

If inflammation is left uncontrolled, Crohn’s disease can lead to long-term damage to the intestines, such as blockages (strictures), abnormal passages (fistulae), or permanent bowel changes. It can also cause growth delays, delayed puberty, and nutrient deficiencies in children. In some cases, surgery may become necessary.

Clinical management and patient considerations

• Multidisciplinary Care: The best results happen when care is managed by a team including gastroenterologists, nurses, dietitians, and mental health experts, all working together to support the child
• Protocolised Monitoring: Regular blood tests help doctors catch any side effects early, such as low blood cell counts or liver issues, often before symptoms appear
• Vaccination Status: Vaccines should be updated before starting treatment, because live vaccines aren’t safe once immunosuppressive therapy begins
• Treatment Adherence: Taking medication consistently and as prescribed is crucial. Missing doses can lead to flare-ups or reduce treatment effectiveness
• Adjunctive Support: A complete care plan includes balanced nutrition, regular physical activity, and emotional support to improve quality of life and treatment success

Future therapeutic direction

Treatment for pediatric IBD is constantly evolving. Researchers are now focused on personalised medicine, which tailors treatment based on a child’s unique biology. For example, genetic testing (like TPMT or NUDT15) may help doctors choose the best drug and dose.

New medications are also being developed to reduce the long-term need for strong immunosuppressant treatments, while still keeping inflammation under control. The future looks promising for more targeted and effective therapies.

Summary

Immunomodulators are a key part of treating Crohn’s disease in children. They calm the immune system, help the intestines heal, reduce the need for steroids, and support healthy growth.

Main types include:

• Thiopurines (azathioprine, mercaptopurine): Often the first choice for maintenance treatment, but require regular blood tests
• Methotrexate: Used if thiopurines cause side effects or if the disease affects areas outside the gut
• Calcineurin inhibitors: Used in severe cases as a short-term “bridge” to other treatments

Using immunomodulators together with biologics often provides the best results, helping treatments last longer and work more effectively. With careful monitoring and a supportive care team, these medicines play a vital role in keeping the disease under control and improving a child’s quality of life.

FAQs

What are immunomodulators?

They are medicines that calm an overactive immune system, reducing gut inflammation in Crohn's disease.

How long do they take to work?

They work slowly, often taking 2-3 months to show full effect. Your doctor will use other treatments as a bridge during this time.

Are they safe for children?

Yes, they are commonly used and closely monitored. The risks of uncontrolled Crohn's disease are typically much greater than the risks of the medication when managed properly.

Will my child be on them forever?

Not necessarily. Treatment length is personalised. Some children need them for years, while others may switch to or stop medication if the disease remains in long-term remission.

Do they affect growth?

No. By controlling inflammation, they actually help protect your child's growth, weight gain, and normal puberty development.

What are the main side effects?

Most are mild and monitored with regular blood tests. Contact your doctor about unusual bruising, frequent fevers, severe fatigue, or new abdominal pain.

What about vaccines?

Your child should be up-to-date on vaccines before starting. Live vaccines (like MMR or chickenpox) are avoided during treatment, but others are safe and recommended.

Can they be used with other drugs?

Yes. They are often combined with biologic drugs to increase effectiveness and prevent the body from forming antibodies against the biologic.